[go: up one dir, main page]

CL2019001715A1 - Estructura cristalina de gremlina 1 y anticuerpo inhibidor. - Google Patents

Estructura cristalina de gremlina 1 y anticuerpo inhibidor.

Info

Publication number
CL2019001715A1
CL2019001715A1 CL2019001715A CL2019001715A CL2019001715A1 CL 2019001715 A1 CL2019001715 A1 CL 2019001715A1 CL 2019001715 A CL2019001715 A CL 2019001715A CL 2019001715 A CL2019001715 A CL 2019001715A CL 2019001715 A1 CL2019001715 A1 CL 2019001715A1
Authority
CL
Chile
Prior art keywords
gremlina
gremlin
crystal structure
inhibitory antibody
antibody
Prior art date
Application number
CL2019001715A
Other languages
English (en)
Inventor
Neesha Dedi
Breda Twomey
Michael John Wright
Gareth Davies
David James Mcmillan
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2019001715A1 publication Critical patent/CL2019001715A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

ESTA INVENCIÓN SE REFIERE A CRISTALES DE LA PROTEÍNA GREMLINA 1 HUMANA Y A LA PROTEÍNA DE GREMLINA 1 HUMANA EN LA FORMA DE UN COMPLEJO CON UN ANTICUERPO INHIBIDOR. LA INVENCIÓN TAMBIÉN SE REFIERE A LA ESTRUCTURA DE GREMLINA 1 HUMANA (POR SÍ MISMA, O EN UN COMPLEJO CON EL ANTICUERPO) Y A LOS USOS DE ESTAS ESTRUCTURAS EN LA SELECCIÓN DE AGENTES QUE MODULAN LA ACTIVIDAD DE GREMLINA 1. LA INVENCIÓN PROPORCIONA ADEMÁS ANTICUERPOS QUE SE UNEN A UN SITIO INHIBIDOR ALOSTÉRICO EN LA GREMLINA 1, JUNTO CON LAS COMPOSICIONES FARMACÉUTICAS Y A LOS USOS MÉDICOS DE TALES ANTICUERPOS Y AGENTES IDENTIFICADOS POR LOS MÉTODOS DE SELECCIÓN.
CL2019001715A 2016-12-19 2019-06-19 Estructura cristalina de gremlina 1 y anticuerpo inhibidor. CL2019001715A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1621635.0A GB201621635D0 (en) 2016-12-19 2016-12-19 Crystal structure

Publications (1)

Publication Number Publication Date
CL2019001715A1 true CL2019001715A1 (es) 2019-11-29

Family

ID=58284547

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001715A CL2019001715A1 (es) 2016-12-19 2019-06-19 Estructura cristalina de gremlina 1 y anticuerpo inhibidor.

Country Status (27)

Country Link
US (3) US10947304B2 (es)
EP (1) EP3555129A2 (es)
JP (1) JP7097364B2 (es)
KR (1) KR102557216B1 (es)
CN (1) CN110099924B (es)
AR (1) AR110394A1 (es)
AU (1) AU2017384471B2 (es)
BR (1) BR112019010903A2 (es)
CA (1) CA3045742A1 (es)
CL (1) CL2019001715A1 (es)
CO (1) CO2019006073A2 (es)
EA (1) EA201991511A1 (es)
EC (1) ECSP19051912A (es)
GB (1) GB201621635D0 (es)
IL (1) IL267287A (es)
MA (1) MA47669A (es)
MX (1) MX2019006630A (es)
MY (1) MY202395A (es)
PE (1) PE20191542A1 (es)
PH (1) PH12019501319A1 (es)
RU (1) RU2769285C2 (es)
TN (1) TN2019000188A1 (es)
TW (1) TWI787223B (es)
UA (1) UA126025C2 (es)
UY (1) UY37528A (es)
WO (1) WO2018115017A2 (es)
ZA (1) ZA201903810B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) * 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
DK3806898T3 (da) 2018-06-18 2025-12-22 UCB Biopharma SRL Gremlin-1-antagonist til anvendelse i behandling af cancer
EP4277927A4 (en) * 2021-01-18 2025-07-23 Suzhou Transcenta Therapeutics Co Ltd NEW ANTI-GREMLIN-1 ANTIBODIES
BR112023018204A2 (pt) * 2021-03-11 2023-10-24 Univ Shanghai Jiaotong Método de tratamento de doenças usando antagonistas de gremlin1
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
US20250257123A1 (en) * 2022-04-20 2025-08-14 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
UY40783A (es) 2023-06-12 2024-12-31 Amgen Inc Proteínas de unión a agonistas del receptor beta de linfotoxina

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
EP0744958B1 (en) 1994-01-31 2003-06-25 Trustees Of Boston University Polyclonal antibody libraries
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20020159986A1 (en) 2001-01-12 2002-10-31 John Langenfeld Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
AU2003285578B2 (en) 2002-12-03 2010-07-15 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20120202710A1 (en) 2003-09-09 2012-08-09 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US20090203041A1 (en) 2006-04-21 2009-08-13 Wei Shi Bmp4 inhibitors
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US8383349B2 (en) 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
ES2622460T3 (es) 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
WO2013137686A1 (ko) 2012-03-15 2013-09-19 서울대학교 산학협력단 그렘린-1에 대한 항체
SG11201506459PA (en) 2013-03-14 2015-09-29 Regeneron Pharma Human antibodies to grem 1
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
DK3806898T3 (da) 2018-06-18 2025-12-22 UCB Biopharma SRL Gremlin-1-antagonist til anvendelse i behandling af cancer

Also Published As

Publication number Publication date
AU2017384471B2 (en) 2024-08-22
EA201991511A1 (ru) 2019-11-29
US20190330323A1 (en) 2019-10-31
TW201837052A (zh) 2018-10-16
PE20191542A1 (es) 2019-10-23
NZ754018A (en) 2024-07-26
BR112019010903A2 (pt) 2019-10-01
JP7097364B2 (ja) 2022-07-07
PH12019501319A1 (en) 2020-03-02
WO2018115017A3 (en) 2019-02-07
ZA201903810B (en) 2020-12-23
GB201621635D0 (en) 2017-02-01
US20210163586A1 (en) 2021-06-03
AU2017384471A1 (en) 2019-06-13
CN110099924A (zh) 2019-08-06
RU2769285C2 (ru) 2022-03-30
MX2019006630A (es) 2019-08-21
EP3555129A2 (en) 2019-10-23
WO2018115017A2 (en) 2018-06-28
CA3045742A1 (en) 2018-06-28
US10947304B2 (en) 2021-03-16
CN110099924B (zh) 2023-11-10
MY202395A (en) 2024-04-25
UY37528A (es) 2018-07-31
AR110394A1 (es) 2019-03-27
RU2019122648A (ru) 2021-01-19
ECSP19051912A (es) 2019-07-31
US11807680B2 (en) 2023-11-07
KR20190093658A (ko) 2019-08-09
IL267287A (en) 2019-08-29
US20240076365A1 (en) 2024-03-07
MA47669A (fr) 2020-01-08
US12473355B2 (en) 2025-11-18
JP2020511946A (ja) 2020-04-23
RU2019122648A3 (es) 2021-07-02
KR102557216B1 (ko) 2023-07-18
TN2019000188A1 (en) 2020-10-05
CO2019006073A2 (es) 2019-06-19
TWI787223B (zh) 2022-12-21
UA126025C2 (uk) 2022-08-03

Similar Documents

Publication Publication Date Title
CL2019001715A1 (es) Estructura cristalina de gremlina 1 y anticuerpo inhibidor.
CO2021003036A2 (es) Compuestos de anillo fusionado
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
ECSP18005520A (es) Anticuerpos de factor xi y métodos de uso
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
MX2016010296A (es) Compuestos farmaceutios.
MX2018003196A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
MX2017005457A (es) Metodos y compuestos agonistas de gip.
EP3496753A4 (en) PD-1 ANTIBODY FORMULATION
EP4003523A4 (en) ANTI-PD-1/LAG3/TIGIT TRISPECIFIC ANTIBODIES AND ANTI-PD-1/LAG3 BISPECIFIC ANTIBODIES
EP3746120A4 (en) ANTI-PD-1 ANTIBODY
IL285134A (en) Therapeutic antibody formulation
IL282813A (en) Antibody formulation
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
MX2019012522A (es) Compuestos y metodos terapeuticos.
EP3432925A4 (en) ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
EP3833691A4 (en) HUMAN PD-L1 ANTIBODIES
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
IL280101A (en) Peptide compounds and therapeutic uses of same
EP3434283A4 (en) MEDICAL COMPOSITION WITH A FAB 'FRAGMENT OF A HUMAN ANTI-NGF ANTIBODY AGAINST PEG
IL272443A (en) Glycyrrhetinic acid derivatives for treating hyperkalemia
EP3897844C0 (en) PHARMACEUTICAL COMBINATION OF ANTI-CEACAM6 AND ANTI-TIM3 ANTICOPRS